Hypophosphatemic osteomalacia caused by adefovir dipivoxil: case report and literature review
10.3760/cma.j.issn.1671-7368.2018.04.015
- VernacularTitle:阿德福韦酯致低磷性骨软化症一例及79例文献分析
- Author:
Maoling YUAN
1
;
Lei WANG
;
Jian YU
;
Min WU
Author Information
1. 213000,苏州大学附属第三医院常州市第一人民医院老年科
- Keywords:
Anti-retrovviral agents;
Adefovir dipivoxil;
Osteomalacia;
Fanconi syndrome;
Hypophosphatemia
- From:
Chinese Journal of General Practitioners
2018;17(4):307-309
- CountryChina
- Language:Chinese
-
Abstract:
A 61-years male patients with chronic hepatitis B developed hypophosphatemic osteomalacia following long-term use of adefovir dipivoxil in our hospital.With "adefovir dipivoxil" and "osteomalacia" as the search terms,we searched Wanfang database and Chinese Biomedical bibliographic database since 2005,and retrieved 79 cases of adefovir dipivoxil-induced hypophosphatemic osteomalacia.Of the 80 cases,there were 63 males and 17 females with a mean age of (52 ± 11) years.The average duration of disease to first diagnosis made was 17 months,the average duration of adefovir dipivoxil administration to the onset of the disease was 62 months,and the average duration of hepatitis B was 11 years.The most common clinical manifestation was progressive bone pain in all parts of the body (80/80 cases);the most common laboratory finding was decreased serum phosphorus (80/80 cases),followed by abnormal urine tests (55/56 cases) including increased urinary phosphorus,urinary protein and positive urinary occult blood.The X-ray,CT and MRI showed different degrees of decreased bone density,osteoporosis,and bone fracture in severe patients (76/77 cases).It is suggested that clinicians should pay attention to the renal damage during the treatment of adefovir dipivoxil,and the renal function,electrolyte and bone density should be monitored regularly.
